Abstract
Central Neurocytomas (CNs) are uncommon tumors of central nervous system, arising from neuronal cells. Mostly these tumors are intraventricular and commonly occurs at the level of the “Foramen of Monro”. However, recently cases of “Extraventricular Neurocytoma” have also been reported. Typically, CNs are associated with favorable outcome. Best long term prognosis, in terms of local control and survival is achieved by maximal safe surgical resection, which is considered as ideal therapeutic option. However, management of recurrent or residual CNs remains controversial. Treatment options for patients with recurrent or residual CNs includes reoperation, radiotherapy or chemotherapy. Use of conventional radiotherapy in recurrent or residual CNs is associated with long term complications in the form of cognitive abnormalities and risk of developing secondary malignancies. Recently, Gamma Knife Radiosurgery is used in patients with recurrent or residual CNs as an alternative treatment option to conventional radiotherapy. Studies have reported that Gamma Knife Radiosurgery provides safe and effective alternative treatment option for recurrent or residual CNs, by eliminating the long term side effects of conventional radiotherapy. However, these are based on results of limited number of studies, with small sample sizes, with no control groups. Randomized control trials or larger studies are required to confirm the effectiveness of Gamma knife Radiosurgery in recurrent or residual CNs. This paper reviews the findings of case series and case reports that contribute to the effectiveness of Gamma knife Radiosurgery in CNs.
Highlights
Central neurocytomas (CNs) are unusual tumors of the central nervous system, characterized by midline intraventricular location at the level of “Foramen of Monro” [1]
A comparison of gross total resection with subtotal resection showed no significant difference in survival or local control
In asymptomatic patients with tumor
Summary
Central neurocytomas (CNs) are unusual tumors of the central nervous system, characterized by midline intraventricular location at the level of “Foramen of Monro” [1]. It was first described by Hassoun et al [2], in 1982, who reported two cases of Central neurocytomas and defined these tumors as a different pathological entity. Since the original description by Hassoun et al [2], there has been a steady increase in recognition of this entity Despite their increased recognition, CNs remain rare neoplasms of the central nervous system. The incidence of this tumor is only 0.25-0.5% of all brain tumors [2,3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
